| P50 | author | Olavi Pelkonen | Q28028673 |
| P2093 | author name string | Jukka Hakkola | |
| | Heikki Vapaatalo | |
| | Jukka Mäenpää | |
| | Marjo Volotinen | |
| P2860 | cites work | Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1. | Q24538817 |
| | Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy | Q24676890 |
| | New perspectives in aqueous humor secretion and in glaucoma: the ciliary body as a multifunctional neuroendocrine gland | Q28290062 |
| | Pharmacological therapy for glaucoma: a review | Q30860458 |
| | Current management of glaucoma | Q33199545 |
| | Bench to bedside: Pharmacogenomics, adverse drug interactions, and the cytochrome P450 system | Q34466778 |
| | Inhibition and induction of human cytochrome P450 (CYP) enzymes | Q34487744 |
| | Genetic basis of glaucoma | Q34553228 |
| | Targeting outflow facility in glaucoma management | Q35174019 |
| | Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects | Q35257739 |
| | Ophthalmic drug delivery considerations at the cellular level: drug-metabolising enzymes and transporters | Q36316835 |
| | Glaucoma screening: current trends, economic issues, technology, and challenges | Q36427904 |
| | Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects. | Q36762112 |
| | Role of CYP1B1 in glaucoma | Q36960115 |
| | Barriers to glaucoma drug delivery | Q37111497 |
| | Expression of cytochrome P450 (CYP) enzymes in human nonpigmented ciliary epithelial cells: induction of CYP1B1 expression by TCDD. | Q39867733 |
| | Pharmacokinetics of topically applied ophthalmic drugs | Q40328899 |
| | The mechanism of timolol in lowering intraocular pressure. In the normal eye. | Q40963886 |
| | Recent advances in molecular genetics of glaucomas | Q41595926 |
| | Transport of timolol and tilisolol in rabbit corneal epithelium | Q42502203 |
| | Association of CYP2D6 single-nucleotide polymorphism with response to ophthalmic timolol in primary open-angle Glaucoma--a pilot study. | Q42868524 |
| | Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes | Q43242688 |
| | Drug transporter and cytochrome P450 mRNA expression in human ocular barriers: implications for ocular drug disposition | Q43452684 |
| | Rate of response to latanoprost or timolol in patients with ocular hypertension or glaucoma | Q44674915 |
| | Cytochrome oxidase 2D6 gene polymorphism in primary open-angle glaucoma with various effects to ophthalmic timolol | Q46089600 |
| | Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. | Q51648124 |
| | Association between low plasma levels of ophthalmic timolol and haemodynamics in glaucoma patients. | Q53855923 |
| | Prevalence of open-angle glaucoma in central Sweden. The Tierp Glaucoma Survey. | Q53989484 |
| | Timolol Metabolism in Human Liver Microsomes Is Mediated Principally by CYP2D6 | Q58734950 |
| P433 | issue | 5 | |
| P304 | page(s) | 297-303 | |
| P577 | publication date | 2011-05-01 | |
| P1433 | published in | Basic and Clinical Pharmacology and Toxicology | Q15724438 |
| P1476 | title | Metabolism of ophthalmic timolol: new aspects of an old drug | |
| P478 | volume | 108 | |